Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-29
2010-06-29
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S141000, C546S146000
Reexamination Certificate
active
07745460
ABSTRACT:
The present invention provides compounds having formula (I):and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
REFERENCES:
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5149780 (1992-09-01), Plow et al.
patent: 5288854 (1994-02-01), Diamond et al.
patent: 5298492 (1994-03-01), Neustadt et al.
patent: 5340800 (1994-08-01), Liu et al.
patent: 5397791 (1995-03-01), Hartman et al.
patent: 5424399 (1995-06-01), Arnaout
patent: 5470953 (1995-11-01), Gallatin et al.
patent: 5585359 (1996-12-01), Breslin et al.
patent: 5597567 (1997-01-01), Whitcup et al.
patent: 5936089 (1999-08-01), Carpino et al.
patent: 5973188 (1999-10-01), Alig et al.
patent: 6204280 (2001-03-01), Gante et al.
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6331640 (2001-12-01), Fotouhi et al.
patent: 6340679 (2002-01-01), Peyman et al.
patent: 6358976 (2002-03-01), Wityak et al.
patent: 6515124 (2003-02-01), Fotouhi et al.
patent: 6524581 (2003-02-01), Adamis
patent: 6605597 (2003-08-01), Zablocki et al.
patent: 6653478 (2003-11-01), Urbanski et al.
patent: 6667318 (2003-12-01), Burdick et al.
patent: 6670321 (2003-12-01), Adamis
patent: 6803384 (2004-10-01), Fotouhi et al.
patent: 6872735 (2005-03-01), Burdick et al.
patent: 7211586 (2007-05-01), Fenton et al.
patent: 2002/0115692 (2002-08-01), Archibald et al.
patent: 2002/0119994 (2002-08-01), Burdick et al.
patent: 2002/0132807 (2002-09-01), Wang et al.
patent: 2002/0177591 (2002-11-01), O'Donnell et al.
patent: 2003/0044406 (2003-03-01), Dingivan
patent: 2003/0068320 (2003-04-01), Dingivan
patent: 2003/0166630 (2003-09-01), Auvin et al.
patent: 2004/0006236 (2004-01-01), Fotouhi et al.
patent: 2004/0028648 (2004-02-01), Adamis
patent: 2004/0038973 (2004-02-01), Nahra et al.
patent: 2004/0058968 (2004-03-01), Burdick et al.
patent: 2004/0120960 (2004-06-01), Jardieu et al.
patent: 2004/0122047 (2004-06-01), Fenton et al.
patent: 2005/0080119 (2005-04-01), Fotouhi et al.
patent: 2006/0281739 (2006-12-01), Gadek et al.
patent: 2008/0182839 (2008-07-01), Shen et al.
patent: 2009/0155176 (2009-06-01), Burnier et al.
patent: 314863 (1989-05-01), None
patent: 362526 (1990-04-01), None
patent: 362531 (1990-04-01), None
patent: 0656789 (1997-12-01), None
patent: 4193895 (1992-07-01), None
patent: WO 90/03400 (1990-04-01), None
patent: WO 90/10652 (1990-09-01), None
patent: WO 90/13316 (1990-11-01), None
patent: WO 91/19511 (1991-12-01), None
patent: WO 92/03473 (1992-03-01), None
patent: WO 94/03481 (1994-02-01), None
patent: WO 94/11400 (1994-05-01), None
patent: WO 95/04531 (1995-02-01), None
patent: WO 95/28170 (1995-10-01), None
patent: WO 96/09836 (1996-04-01), None
patent: WO 98/46599 (1998-10-01), None
patent: WO 99/49856 (1999-10-01), None
patent: WO 00/21920 (2000-04-01), None
patent: WO 00/21920 (2000-04-01), None
patent: WO 00/38714 (2000-07-01), None
patent: WO 00/44731 (2000-08-01), None
patent: WO 01/27102 (2001-04-01), None
patent: WO 01/58853 (2001-08-01), None
patent: WO 01/87840 (2001-11-01), None
patent: WO 02/50080 (2002-06-01), None
patent: WO 02/059114 (2002-08-01), None
patent: WO 02/098426 (2002-12-01), None
patent: WO 2004/026406 (2004-04-01), None
patent: WO 2005/014532 (2005-02-01), None
patent: WO 2005/014533 (2005-02-01), None
patent: WO 2005/044817 (2005-05-01), None
Lupus erythematosus [online], [retrieved on Dec. 28, 2006]. Retrieved from the internet, URL; http://en.wikipedia.org/wiki/Lupus—erythematosus>.
Gadek, et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 2002; 295: 1086-9.
Gao, et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp Eye Res. Apr. 2004;78(4):823-35.
Keating, et al. Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the alphal subunit of lymphocyte function-associated antigen-1. Protein Sci. 2006; 15(2):290-303.
Keating, et al. Putting the pieces together : Contribution of fluorescence polarization assays to small molecule lead optimization. Proc. SPIE. 2000; vol. 3913, p. 128-137. (Online Publication Date: Jul. 2, 2003).
Shimaoka, et al. Small molecule integrin antagonists that bind to the β2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity. 2003; 19(3): 391-402.
Boschelli, D. H.; et al., “3-Alkoxybenzo[b]thiophene-2-carboxamides as Inhibitors of Neutrophil-Endothelial Cell Adhesion”,J. Med. Chem.,1994, 37(6): 717-718.
Boschelli, D. H.; et al.,“Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo[b]thiophene-, Benzufuran-, Indole-, and Naphthalene-2-carboxamides: Identification of PD 144795 as an Antiinflammatory Agent”,J. Med. Chem.,1995, 38: 4597-4614.
Chang, Y. H.; et al., “Effects of pharmacologic agents on the reversed passive Arthus reaction in the rat”Eur. J. Pharmacol,1981, 69(2):155-164.
Cosimi, A. B.; et al., “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts1,”J. Immunol.,1990, 144(12): 4604-4612.
Diamond, M., et al., “The dynamic regulation of integrin adhesiveness”,Current Biology,1994, 4(6): 506-532.
Fischer, A.; et al., “Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation”,The Lancet,1986, 2: 1058-1060.
Gorski, A.; “The role of cell adhesion molecules in immunopathology”,Immunology Today,1994, 15: 251-255.
Hildreth, J., et al., “Monoclonal Antibodies Against Porcine LFA-1: Species Cross-Reactivity and Functional Effects of β-Subunit-Specific Antibodies”, Molecular Immunology, 1989, 26(9): 883-895.
Kavanaugh, A.; et al., “Treatment of Refractory Rheumatoid Arthritis with a Monoclonal Antibody to Intercellular Adhesion Molecule 1”,Arthritis Rheum.,1994, 37(7): 992-1004.
Kishimoto, T. K., et al., “Integrins, ICAMs, and Selectins: Role and Regulation of Adhesion Molecules in Neutrophil Recruitment to Inflammatory Sites”,Adv. Pharmacol.,1994, 25: 117-169.
Le Mauff, B.; et al., “Effect of Anti-LFA1 (CD11a) Monoclonal Antibodies in Acute Rejection in Human Kidney Transplantation”,Transplantation,1991, 52(2): 291-295.
Musza, L. L.; et al., “Potent New Cell Adhesion Inhibitory Compounds from the Root ofTrichilia rubra”, Tetrahedron,1994, 50(39): 11369-11378.
Plobeck et al., “New Diarylmethylpiperazines as Potent and Selective Nonpeptidic δ Opioid Receptor Agonists with Increased in Vitro Metabolic Stability”,J.Med.Chem.,2000, 43:3878-3894.
Rothlein, R., et al., “1. Leukocyte Adhesion in Inflammation: From Discovery to the Clinic”,Adhesion Molecules;Wegner, C. D., Ed.; 1994, 1-8.
Sanfilippo, P. J.; et al. “Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion”,J. Med. Chem.,1995, 38: 1057-1059.
Springer, T., “Adhesion Receptors of the immune system”,Nature,1990, 346: 425-434.
International Search Report from corresponding International Application No. PCT/US2004/036942, (2005).
Burdick, et al. N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: Structure-activity relationship of the benzoyl moiety. Bioorganic & Medicinal Chemistry Letters. 2004; 14(9): 2055-9.
Burdick, et al. N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship. Bioorganic & Medicinal Chemistry Letters. 2004; 13(6): 1015-8.
Gadek, et al. Generation of an LFA-1 antagonist by the transfer of the
Barr Kenneth
Oslob Johan D.
Shen Wang
Zhong Min
Saeed Kamal A
SARcode Corporation
Wilson Sonsini Goodrich & Rosati
Young Shawquia
LandOfFree
Modulators of cellular adhesion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of cellular adhesion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of cellular adhesion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159892